LATEST PRESS RELEASE

Amorfix Announces The Development Of Antibodies That Bind to Misfolded Fas Receptor Protein As A Potential Treatment For Cancer

May 16, 2012

Amorfix has developed antibodies that selectively target and bind to misfolded Fas receptor protein expressed on the cell surface of cancer cells.

Download PDF

Amorfix Closes Private Placement Offering

May 14, 2012

Amorfix has closed a non-brokered private placement (the Offering) pursuant to which a total of 2,585,000 units (Units) were issued at a price of $0.40 per unit for gross proceeds of $1,034,000.

Download PDF

Amorfix Announces Private Placement

May 08, 2012

Amorfix intends to complete, subject to regulatory approval, a non-brokered private placement of up to 2,500,000 units (Units) at a price of $0.40 per Unit, for gross proceeds of $1,000,000, of which commitments to subscribe for 2,200,000 units have been received.

Download PDF

View All Amorfix Press Releases

EVENTS

The Alzheimer's Association 2011 International Conference on Alzheimer's Disease

July 16 -21, 2011 : Paris, France

Development of An Ultra Sensitive Assay for Detection of Aggregated Beta Amyloid in Human CSF

Click here to visit site

10th International Conference on Alzheimer's and Parkinson's Diseases

March 9-13, 2011: Barcelona, Spain

Detection of β-Amyloid Aggregates in CSF From Transgenic Animal Models of Alzheimer's Disease Using the Amorfix Aggregated Abeta Assay (A4)

Click here to visit site

View All Events

TSX:AMF listed

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.

Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.

amorfix life sciences